Advances in the study of LNPs for mRNA delivery and clinical applications
B Wang, B Shen, W Xiang, H Shen - Virus Genes, 2024 - Springer
Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for
transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 …
transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 …
Aluminum oxyhydroxide-Poly (I: C) combination adjuvant with balanced immunostimulatory potentials for prophylactic vaccines
Z Yao, Z Liang, M Li, H Wang, Y Ma, Y Guo… - Journal of Controlled …, 2024 - Elsevier
The development of high-purity antigens promotes the urgent need of novel adjuvant with
the capability to trigger high levels of immune response. Polyinosinic-polycytidylic (Poly (I …
the capability to trigger high levels of immune response. Polyinosinic-polycytidylic (Poly (I …
Evaluating the breadth of nucleic acid-based payloads delivered in lipid nanoparticles to establish fundamental differences in development
J Li, C Foged - Expert Opinion on Drug Delivery, 2024 - Taylor & Francis
Introduction Nucleic acid (NA)-based therapeutics have shown great potential for
downregulating or augmenting gene expression, and for promising applications, eg, protein …
downregulating or augmenting gene expression, and for promising applications, eg, protein …
Polymersomal poly (I: C) self‐magnifies antitumor immunity by inducing immunogenic cell death and systemic immune activation
J Wang, B Guo, Z Sun, S Zhao, L Cao… - Advanced …, 2024 - Wiley Online Library
Immunotherapy has emerged as a powerful weapon against lung cancer, yet only a fraction
of patients respond to the treatment. Poly (I: C)(PIC) effectively triggers both innate and …
of patients respond to the treatment. Poly (I: C)(PIC) effectively triggers both innate and …
An immunostimulatory liponanogel reveals immune activation-enhanced drug delivery and therapeutic efficacy in cancer
X Li, C Wu, J Li, J Yu, X Yang, L Yu, C Wang… - Journal of Controlled …, 2024 - Elsevier
The clinical use of immunostimulatory polyinosinic: polycytidylic acid (pIC) for cancer
therapy has been notably limited by its low tumor accumulation and poor cytosolic delivery …
therapy has been notably limited by its low tumor accumulation and poor cytosolic delivery …
HER2 Nanobody-Poly (rhamnose) Conjugates Efficiently Recruit Anti-Rhamnose Antibodies from Serum to the Surface of HER2-Expressing Cells
Recruiting endogenous antibodies to target tumor cells for elimination by the immune
system represents a promising therapeutic strategy. Existing antibody-recruiting molecules …
system represents a promising therapeutic strategy. Existing antibody-recruiting molecules …
Enhanced Cellular Immunity for Hepatitis B Virus Vaccine: A Novel Polyinosinic-Polycytidylic Acid-Incorporated Adjuvant Leveraging Cytoplasmic Retinoic Acid …
X Liu, Q Min, Y Li, S Chen - Biomaterials Research, 2024 - spj.science.org
Conventional aluminum adjuvants exhibit limited cellular immunity. Polyinosinic-
polycytidylic acid (poly I: C) activates cytoplasmic retinoic acid-inducible gene-like receptor …
polycytidylic acid (poly I: C) activates cytoplasmic retinoic acid-inducible gene-like receptor …
Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in quadrivalent influenza vaccine vaccinated mice
There are considerable avenues through which currently licensed influenza vaccines could
be optimized. We tested influenza vaccination in a mouse model with two adjuvants: Sendai …
be optimized. We tested influenza vaccination in a mouse model with two adjuvants: Sendai …
[HTML][HTML] Regulating Immune Responses Induced by PEGylated Messenger RNA–Lipid Nanoparticle Vaccine
H Jo, J Jeoung, W Kim, D Jeoung - Vaccines, 2024 - mdpi.com
Messenger RNA (mRNA)-based therapeutics have shown remarkable progress in the
treatment and prevention of diseases. Lipid nanoparticles (LNPs) have shown great …
treatment and prevention of diseases. Lipid nanoparticles (LNPs) have shown great …
Porphyromonas gingivalis Vaccine: Antigens and Mucosal Adjuvants
S Wang, T Yan, B Zhang, Y Chen, Z Li - Vaccines, 2024 - mdpi.com
Porphyromonas gingivalis (Pg), a Gram-negative anaerobic bacterium found in dental
plaque biofilm within periodontal pockets, is the primary pathogenic microorganism …
plaque biofilm within periodontal pockets, is the primary pathogenic microorganism …